- Gold off lows, remains heavy as US dollar gains on risk-aversion.
- Rising covid cases and new shutdowns globally weigh on market mood.
- Vaccine optimism ignored as focus remains on covid updates.
Gold’s (XAU/USD) attempts a bounce from weekly lows near $1855, as the bulls recapture the $1860 mark despite the risk-aversion fuelled by the relentless rise in the coronavirus cases on both sides of the Atlantic.
Markets appear to take profits on their short positions after the price once again held onto the critical $1850 support. Further, the yieldless gold derives support from the sell-off in the US Treasury yields amid a lack of demand for riskier assets.
However, gold’s recovery attempts seem shallow, as the haven demand for the US dollar remains in vogue amid the reignition of the global economic concerns. Spiking virus cases and fresh lockdowns announced in the US, Australia and Europe threaten the prospects of an economic recovery, which weigh on the vaccine enthusiasm.
After Pfizer and Moderna, AstraZeneca announced promising results from its covid vaccine trial, adding that the final results from the phase 3 trial is expected in weeks.
Gold Technical levels
Immediate resistance awaits at the $1874 daily high, above which the bulls will gear up for a test of the critical $1891 barrier. To the downside, October low at $1860 could be retested, below which is the next cushion is aligned at $1850/49, the September month low and November 9 low.
Gold: Additional levels
|Today last price||1864.20|
|Today Daily Change||-7.15|
|Today Daily Change %||-0.38|
|Today daily open||1870.32|
|Previous Daily High||1884.9|
|Previous Daily Low||1863.86|
|Previous Weekly High||1965.58|
|Previous Weekly Low||1850.56|
|Previous Monthly High||1933.3|
|Previous Monthly Low||1860|
|Daily Fibonacci 38.2%||1871.9|
|Daily Fibonacci 61.8%||1876.86|
|Daily Pivot Point S1||1861.15|
|Daily Pivot Point S2||1851.99|
|Daily Pivot Point S3||1840.11|
|Daily Pivot Point R1||1882.19|
|Daily Pivot Point R2||1894.07|
|Daily Pivot Point R3||1903.23|
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.